Home   ->   news   ->   Press Releases

Press Releases

WuXi AppTec’s Research Service Division Collaborates with Pelago Bioscience to Provide CETSA® based Target Engagement Assays

Stockholm, Münich, Shanghai, August 1, 2016 –WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that its Research Service Division(RSD) will collaborate with Pelago Bioscience, a Swedish biotech company to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA ®)method.

Target engagement is pivotal to targeted drug efficacy. Pelago’s CETSA method enables target engagement quantifications of the physiologically relevant form of the target in live cells and tissue samples, accelerating the discovery of high quality drugs. The collaboration between WuXi RSD and Pelago will help more pharmaceutical R&D and biotech companies worldwide leverage the CETSA method to develop new and better drugs more quickly and cost-effectively.

“We are excited and very proud to be working with WuXi RSD, adding our target engagement quantifications to their full value chain service portfolio.” said Dr. Michael Dabrowski, CEO of Pelago Bioscience. “This collaboration, with a global service provider will enable more CETSA data to benefit existing and new customers.”

“The CETSA platform is highly complementary to our own structural biology and biophysical assay platforms and capabilities,” said Dr. Steve Yang, Executive Vice President, Chief Operating Officer of WuXi AppTec and head of WuXi RSD, “We are very enthusiastic about the potential of the CETSA platform to rapidly deliver detailed target engagement information to our clients to inform their discovery programs.”

Dr. Ismail Moarefi, Chief Science Officer of Crelux, WuXi RSD’s structural biology subsidiary in Munich, Germany, added,  “By collaborating with Pelago Bioscience we can pool our own expertise in protein production, biophysical assays for hit validation and crystallisation with the CETSA target engagement technology and create a combined platform that informs structure based drug design in a powerful new way ”.

AboutPelago Bioscience AB

Spun out from the Karolinska Institute, Stockholm Sweden, PelagoBioscience AB (http://pelagobio.com) was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages intheir projects. This reduces time and money spent on sub optimal compounds and allows faster development of more efficacious new drugs.See CETSA and Pelago Bioscience explained in 8 minutes or Email Pelago to learn how we can help with all stages of Drug Discovery.

About WuXi AppTec and WuXi RSD

WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfillWuXi’s dream that “every drug can be made and every disease can be treated.”  WuXi’s Research Services Division (RSD) delivers comprehensive target discovery, biology, chemistry and pharmacology services enabling the discovery and development of future therapeutics. Combining RSD’s peer-recognized scientific expertise and WuXi’s fully integrated drug discovery and development platform allows client programs to progress seamlessly from target through to preclinical candidate selection and beyond.

Please visit http://www.wuxiapptec.com

For more information
Pelago Bioscience AB, Michael Dabrowski, CEO, Tel. +46 (0)730 715 334, michael@pelagobio.com
WuXi AppTec, Aaron Shi, Director of Corporate Communications, Tel. +8621 50464362, aaron_shi@wuxiapptec.com

back to top